

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A pharmaceutical formulation comprising an effective amount of acetylsalicylic acid and a compound of formula I,



wherein

R^1 represents $-R^3$ or $-A^1C(O)N(R^4)R^5$ or $-A^1C(O)OR^4$;

A^1 represents C_{1-5} alkylene;

R^2 (which replaces one of the hydrogen atoms in the amidino unit of Pab-H) represents OH, $OC(O)R^6$, $C(O)OR^7$ or $C(O)OCH(R^8)OC(O)R^9$;

R^3 represents H, C_{1-10} alkyl, or C_{1-3} alkylphenyl (which latter group is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen);

R^4 and R^5 independently represent H, C_{1-6} alkyl, phenyl, 2-naphthyl or, when R^1 represents $-A^1C(O)N(R^4)R^5$, together with the nitrogen atom to which they are attached represent pyrrolidinyl or piperidinyl;

R^6 represents C_{1-17} alkyl, phenyl or 2-naphthyl (all of which are optionally substituted by C_{1-6} alkyl or halogen);

R^7 represents 2-naphthyl, phenyl, C_{1-3} alkylphenyl (which latter three groups are optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen), or C_{1-12} alkyl (which latter group is optionally substituted by C_{1-6} alkoxy, C_{1-6} acyloxy or halogen);

R^8 represents H or C_{1-4} alkyl; and

R^9 represents 2-naphthyl, phenyl, C_{1-6} alkoxy or C_{1-8} alkyl (which latter group is

optionally substituted by halogen, C₁₋₆ alkoxy or C₁₋₆ acyloxy); provided that when R¹ represents R³, R³ represents benzyl, methyl, ethyl, *n*-butyl or *n*-hexyl and R² represents C(O)OR⁷, then R⁷ does not represent benzyl;
or a pharmaceutically-acceptable salt thereof.

2 (currently amended). A ~~formulation~~ compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, A¹ represents C₁₋₃ alkylene when R¹ represents -A¹C(O)N(R⁴)R⁵.

3 (currently amended). A ~~formulation~~ compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, R⁴ represents H or C₁₋₆ alkyl when R¹ represents -A¹C(O)N(R⁴)R⁵.

4 (currently amended). A ~~formulation~~ compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, R⁵ represents C₁₋₆ alkyl or C₄₋₆ cycloalkyl when R¹ represents -A¹C(O)N(R⁴)R⁵.

5 (currently amended). A ~~formulation~~ compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, R⁴ and R⁵ together represent pyrrolidinyl when R¹ represents -A¹C(O)N(R⁴)R⁵.

6 (currently amended). A ~~formulation~~ compound of formula I, as defined in Claim 2, wherein, in the compound of formula I, A¹ represents C₁₋₃ alkylene, and R⁴

represents H or C₁₋₃ alkyl and R⁵ represents C₂₋₆ alkyl or C₅₋₆ cycloalkyl, or R⁴ and R⁵ together represent pyrrolidinyl.

7 (currently amended). A formulation~~compound~~ of formula I, as defined in Claim 1, wherein, in the compound of formula I, A¹ represents C₁₋₅ alkylene when R¹ represents -A¹C(O)OR⁴.

8 (currently amended). A formulation~~compound~~ of formula I, as defined in Claim 1, wherein, in the compound of formula I, R⁴ represents C₁₋₆ alkyl when R¹ represents -A¹C(O)OR⁴.

9 (currently amended). A formulation~~compound~~ of formula I, as defined in Claim 7, wherein A¹ represents C₁₋₅ alkylene and R⁴ represents C₁₋₄ alkyl.

10 (currently amended). A formulation~~compound~~ of formula I, as defined in Claim 1, wherein, in the compound of formula I, R³ represents H, C₁₋₁₀ alkyl (which latter group may be linear or, when there are a sufficient number of carbon atoms, may be branched and/or be partially cyclic or cyclic), or C₁₋₃ alkylphenyl (which latter groups is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, be branched), when R¹ represents R³.

11 (currently amended). A formulation~~compound~~ as claimed in Claim 1, wherein, in the compound of formula I, R¹ represents H, linear C₁₋₁₀ alkyl, branched C₃₋₁₀

alkyl, partially cyclic C₄₋₁₀ alkyl, C₄₋₁₀ cycloalkyl, optionally substituted linear C₁₋₃ alkylphenyl, optionally substituted branched C₃ alkylphenyl.

12 (currently amended). A formulation compound as claimed in Claim 11, wherein R¹ represents linear C₁₋₆ alkyl, C₆₋₁₀ cycloalkyl, or optionally substituted linear C₁₋₃ alkylphenyl.

13 (currently amended). A formulation compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, R² represents OH.

14 (currently amended). A formulation compound of formula I, as defined in Claim 1, wherein, in the compound of formula I, R⁶ represents optionally substituted phenyl or C₁₋₁₇ alkyl (which latter group may be linear or, when there are a sufficient number of carbon atoms, may be branched, be cyclic or partially cyclic, and/or be saturated or unsaturated) when R² represents OC(O)R⁶.

15 (currently amended). A formulation compound as claimed in Claim 14 wherein R⁶ represents optionally substituted phenyl, linear C₁₋₄ alkyl, branched C₁₋₃ alkyl or *cis*-oleyl.

16 (currently amended). A formulation compound as claimed in Claim 15 wherein R⁶ represents linear C₁₋₃ alkyl or branched C₃ alkyl.

17 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R⁷ represents optionally substituted phenyl, C₁₋₁₂ alkyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched, cyclic or partially cyclic, and/or saturated or unsaturated), or C₁₋₃ alkylphenyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched) when R² represents C(O)OR⁷.

18 (currently amended). A ~~formulation compound as claimed~~ in Claim 17 wherein R⁷ represents optionally substituted and/or optionally unsaturated linear C₁₋₄ alkyl or optionally substituted and/or optionally unsaturated branched C₃₋₄ alkyl, optionally substituted phenyl, or optionally substituted linear C₁₋₃ alkylphenyl or optionally substituted branched C₃ alkylphenyl.

19 (currently amended). A ~~formulation compound~~ as claimed in Claim 18 wherein R⁷ represents optionally substituted linear C₁₋₄ alkyl or optionally substituted branched C₃₋₄ alkyl, optionally substituted linear C₁₋₃ alkylphenyl or branched C₃ alkylphenyl.

20 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R⁸ represents H or methyl, when R² represents C(O)OCH(R⁸)OC(O)R⁹.

21 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R⁹ represents phenyl, or C₁₋₈ alkyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched and/or cyclic or partially cyclic) when R² represents C(O)OCH(R⁸)OC(O)R⁹.

22 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 20 wherein R⁸ represents H or methyl and R⁹ represents phenyl, C₅₋₇ cycloalkyl, linear C₁₋₆ alkyl, branched C₃₋₆ alkyl or partially cyclic C₇₋₈ alkyl.

23 (currently amended). A ~~formulation compound~~ as claimed in Claim 22 wherein R⁸ represents H and R⁹ represents C₅₋₇ cycloalkyl, linear C₁₋₆ alkyl or partially cyclic C₇₋₈ alkyl.

24 (currently amended). A ~~formulation compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R¹ represents R³ and R³ represents optionally substituted C₁₋₃ alkylphenyl, the optional substituent C₁₋₆ alkyl.

25 (currently amended). A ~~formulation compound~~ as claimed in Claim 24 wherein the substituent is methyl.

26 (currently amended). A ~~formulation compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R² represents C(O)OR⁷ and R⁷ represents

optionally substituted C₁₋₁₂ alkyl, the optional substituent is selected from halogen and C₁₋₆ alkoxy.


27 (currently amended). A formulation compound as claimed in Claim 26 wherein the substituent is selected from chloro and methoxy.

28 (currently amended). A formulation compound as claimed in Claim 1 wherein, in the compound of formula I, when R² represents C(O)OR⁷ and R⁷ represents optionally substituted phenyl, the optional substituent is selected from C₁₋₆ alkyl, C₁₋₆ alkoxy and halogen.

29 (currently amended). A formulation compound as claimed in Claim 28 wherein the substituent is selected from methyl, methoxy and chloro.

30 (currently amended). A formulation compound as claimed in Claim 1 wherein, in the compound of formula I, when R² represents C(O)OR⁷ and R⁷ represents optionally substituted C₁₋₃ alkylphenyl, the optional substituent is nitro.

31 (currently amended). A formulation compound as claimed in Claim 1 wherein the compound of formula I which is



EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOEt
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COO-*n*Bu;
PrIC(O)CH₂CH₂CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
ChNHC(O)CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
(*n*Pr)₂NC(O)CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCC(CH₃)₃;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCC(CH₃)₃;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH(CH₃)OOCCCH₃;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OOCPh;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*i*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*t*BuOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
(*n*Pr)₂NCOCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-OH;
ChNHCOCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OAc;
HOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
HOOCCH₂-(*R*)Cgl-Aze-Pab-O-*cis*-Oleyl;
Cyclooctyl-OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
*t*BuCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
(2-Me)BnOOCCH₂-(*R*)Cgl-Aze-Pab-Z;

$\text{ChCH}_2\text{OOCCH}_2-(R)\text{Cgl-Aze-Pab-Z};$
 $\text{ChOOCCH}_2-(R)\text{Cgl-Aze-Pab-Z};$
 $\text{PhC}(\text{Me})_2\text{OOCCH}_2-(R)\text{Cgl-Aze-Pab-Z};$
 $(\text{Me})_2\text{CHC}(\text{Me})_2\text{OOCCH}_2-(R)\text{Cgl-Aze-Pab-Z};$
 $\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-OMe});$
 $\text{ChCH}_2\text{OOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-OMe});$
 $(2\text{-Me})\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-OMe});$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-Me});$
 $\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-Me});$
 $\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COO-}n\text{Bu};$
 $i\text{PrOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{CH=CH}_2;$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COO-}i\text{Bu};$
 $\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COO-}n\text{Pr};$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{OOCCh};$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{OOCCH}_2\text{Ch};$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}(\text{Me})\text{OOCPh};$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{OOCPh};$
 $\text{BnOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}(\text{Me})\text{OAc};$
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{OAc};$
 $i\text{BuOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{OAc};$
 $\text{MeOOC-C(=CHEt)CH}_2\text{-OOCCH}_2-(R)\text{Cgl-Aze-Pab-Z};$
 $\text{Men-OOCCH}_2-(R)\text{Cgl-Aze-Pab-COOPh}(4\text{-OMe});$ and
 $\text{EtOOCCH}_2-(R)\text{Cgl-Aze-Pab-COOCH}_2\text{CCl}_3.$

32 (currently amended). A formulation compound as claimed in Claim 1 wherein the compound of formula I ~~which is~~

EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂CCl₃;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOnBu;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
Cyclooctyl-OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCCh;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*i*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH
BnOOCCH₂-(*R*)Cgl-Aze-Pab-OH; and
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OAc.

33 (currently amended). A formulation compound of formula I, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R¹ does not represent -A¹C(O)OR⁴.

34 (currently amended). A formulation compound of formula I, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R⁴ and R⁵ do not independently represent H.

35 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R⁶ does not represent C₁₋₁₇ alkyl, when R² represents OC(O)R⁶.

36 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R¹ represents -A¹C(O)OR⁴.

37 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R⁴ and R⁵ independently represent H.

38 (currently amended). A ~~formulation compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R⁶ represents C₁₋₁₇ alkyl, when R² represents OC(O)R⁶.

39-46 (cancelled).

47 (currently amended). A method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a ~~formulation compound of formula I~~ as defined in Claim 1 or claim 52, or a pharmaceutically acceptable salt thereof, to a person suffering from, or susceptible to, such a condition.

48 (original). A method as claimed in Claim 47, wherein the condition is


thrombosis.

49 (original). A method as claimed in claim 47, wherein the condition is hypercoagulability in blood and tissues.

50-51 (cancelled).

52 (new). A formulation as claimed in claim 1, wherein the compound of formula I is $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

53 (new). A combination comprising (a) acetylsalicylic acid and (b) a compound of the formula I,



54 (new). A combination comprising (a) acetylsalicylic acid and (b) the compound $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$ or a pharmaceutically-acceptable salt thereof.

55 (new). A combination comprising (a) acetylsalicylic acid and (b) the compound $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

56 (new). A combination as claimed in Claim 53 which comprises a kit of parts comprising components (a) and (b).

57 (new). A combination product as claimed in Claim 53, in which components (a) and (b) are suitable for sequential, separate and/or simultaneous use in the treatment of a condition where inhibition of thrombin is required.

58 (new). A combination product as claimed in Claim 57, wherein component (a) is combined with component (b).

59 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 53.

60 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 54.

61 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 55.

62 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of a therapeutically effective amount of components (a) and (b) of a combination as claimed in Claim 53 separately,

sequentially or simultaneously.

63 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 53.

64 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 54.

65 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 55.